Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

After over ten years’ of DARPA-funded research, and in collaboration with the NIH, Professor Kieran Clarke has exclusively licensed her novel ketone monoester, ΔG®, to Silicon Valley start-up company HVMN Inc. ΔG® will be used in the world’s first ketone drink for athletes (http://hvmn.com/ketone), for use in training, endurance performance and recovery after exercise.

Papers recently published in Cell Metabolism, FASEB, Frontiers in Physiology and Obesity have caused mounting anticipation of a commercially available product. Since the launch on Monday 6 November 2017, press coverage has been high on both sides of the Atlantic, with articles in The Times, The Independent, Business Insider and Men’s Health (amongst many others).

Professor Clarke continues to collaborate with the NIH and other institutions worldwide on potential applications of ΔG®, including for obesity, metabolic disease, type 2 diabetes and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. 

bottle.jpg

Similar stories

Christoph Treiber awarded ERC Starting Grant to investigate the origins of behavioural diversity

Congratulations are in order for postdoctoral research scientist Dr Christoph Treiber who has been awarded a Starting Grant from the European Research Council. His funded project will investigate the genetic components that may contribute to diversity of brain function and behaviour.

Switch with a spring: a new model for sleep regulation

New collaborative research led by the Vyazovskiy Group has shed new light on the role of the hypothalamus in the transition between sleep and wake states.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

Drug could help diabetic hearts recover after a heart attack

New research led by Associate Professor Lisa Heather has found that a drug known as molidustat, currently in clinical trials for another condition, could reduce risk of heart failure after heart attacks.